Xin Lang Cai Jing·2025-09-19 06:07Company Overview - WuXi AppTec, established on December 1, 2000, is located in Shanghai and Hong Kong, and was listed on May 8, 2018. The company provides a comprehensive platform for the discovery, development, and manufacturing of small molecule chemical drugs, serving global pharmaceutical companies [1][2]. Financial Performance - For the first half of 2025, WuXi AppTec achieved a revenue of 20.799 billion yuan, representing a year-on-year growth of 20.64%. The net profit attributable to shareholders was 8.561 billion yuan, showing a significant increase of 101.92% year-on-year [2]. - The company has distributed a total of 13.027 billion yuan in dividends since its A-share listing, with 9.373 billion yuan distributed over the past three years [2]. Stock Performance - As of September 19, WuXi AppTec's stock price was 105.22 yuan per share, with a market capitalization of 310.558 billion yuan. The stock has increased by 95.90% year-to-date, with a slight decline of 0.24% over the past five trading days [1]. - The trading volume on September 19 was 3.397 billion yuan, with a turnover rate of 1.28% [1]. Shareholder Structure - As of June 30, 2025, the second-largest shareholder is Hong Kong Central Clearing Limited, holding 302 million shares, an increase of 56.0239 million shares from the previous period. Other notable shareholders include Huaxia SSE 50 ETF and China Europe Medical Health Mixed A [3]. Industry Classification - WuXi AppTec is classified under the pharmaceutical and biotechnology sector, specifically in medical services and contract research organization (CRO) services. The company is associated with concepts such as cell therapy, precision medicine, innovative drugs, and overseas expansion [2].